Navarixin is under clinical development by Merck and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Navarixin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Navarixin (MK-7123, SCH 527123) is under development for the treatment of solid tumors including non-small cell lung cancer, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer and metastatic microsatellite stable colorectal cancer. It is administered orally. SCH 527123 (MK-7123) is a small molecule human CXCR1 and CXCR2 receptor antagonist. SCH 527123 also acts as an inhibitor of neutrophil recruitment, mucus production and goblet cell hyperplasia.
It was under development for the treatment of psoriasis and COPD (Chronic Obstructive Pulmonary Disease) and severe asthma.
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
For a complete picture of Navarixin’s drug-specific PTSR and LoA scores, buy the report here.